资讯

PipelineReview.com13 小时
aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American ...
Findings demonstrate ATYR2810’s anti-tumor activity and increased survival in a model of glioblastoma multiforme (GBM), a primary form of brain cancer.